Skip to main content
Log in

On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin

  • Originals
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

The pharmacokinetics of pengitoxin has been studied in 28 healthy subjects after intravenous and oral administration. The mean plasma concentration 24 h after 0.5 mg i.v. was 5.2 ng · ml−1. Following an open two-compartment model a mean elimination half-life of 60.5 h (24.9 to 103.5 h) and a mean volume of distribution (Vdarea) of 66.91 (31.8 to 109.61) were calculated. Absorption calculated by comparison of the AUC0-∞-values amounted to 99%. Within 4 days, 16.7% (11.7 to 21.1%) or 27.8% (18.4 to 33.7%) (0.5 mg i.v. or 1.2 mg p.o.) was excreted in urine. After pengitoxin 0.5 mg i.v. total body clearance and renal clearance were 13.3 ml · min−1 (7.0 to 18.6 ml · min−1) and 3.0 ml · min−1 (1.9 to 3.9 ml · min−1) respectively. The elimination half-life of pengitoxin is longer than that of digoxin and distinctly shorter than that of digitoxin, whilst its distribution volume and clearance are closer to those of digitoxin than of digoxin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  • Belz GG, Nübling H (1975) Half life in plasma following repetitive application ofβ-acetyl-digoxin in man. Klin Wochenschr 53:543–544

    Google Scholar 

  • Blumenthal HP (1979) Pharmacokinetic models for digitoxin. In: Greeff K, Rietbrock N (eds) Digitoxin. Schattauer-Verlag, Stuttgart, p 52–60

    Google Scholar 

  • Fiehring H, Sundermann A, Knappe J (1983) Penta-acetyl-gitoxin — ein neues Herzglykosid. Dtsch Gesundheitswes 18:1334–1338

    Google Scholar 

  • Greenblatt DJ, Koch-Weser J (1975) Clinical pharmacokinetics. N Engl J Med 293:702–705

    Google Scholar 

  • Hartley HO (1948) The estimation of non-linear parameters by internal least squares. Biometrika 35:32–45

    Google Scholar 

  • Haustein KO (1978) Measurement of plasma glycoside level following pengitoxin administration. Eur J Clin Pharmacol 13:389–391

    Google Scholar 

  • Haustein KO (1983) 20 Jahre Pengitoxin — eine Übersicht. Arzneimittelforsch (Drug Res) (in press)

  • Haustein KO, Pachaly C, Megges R, Franke P (1978a) Investigation into species-specific deacylation of penta-acetyl-gitoxin. Eur J Clin Pharmacol 14:425–430

    Google Scholar 

  • Haustein KO, Pachaly C, Murawski D (1978b) Pharmacokinetic investigations with3H-penta-acetyl-gitoxin in volunteers and patients with respect to the occurrence of drug latentiation. Int J Clin Pharmacol 16:285–289

    Google Scholar 

  • Hüller G, Haustein KO, Murawski D (1981) On the plasmaprotein binding of 16-acetyl-gitoxin. Int J Clin Pharmacol 19:200–202

    Google Scholar 

  • Keller F, Blumenthal HP, Maertin K, Rietbrock N (1977) Overall pharmacokinetics during prolonged treatment of healthy volunteers with digoxin andβ-methyl-digoxin. Eur J Clin Pharmacol 12:387–392

    Google Scholar 

  • Koup JR, Greenblatt DJ, Jusko WJ, Smith TW, Koch-Weser J (1975) Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm 3:181–192

    Google Scholar 

  • Nelder JA, Mead R (1965) A simplex method for function minimizing. Computer J 7:308–313

    Google Scholar 

  • Repke K, Megges R (1963) Die Entwicklung eines neuen Herzglykosidpräparates mit großer therapeutischer Breite (Pentaacetyl-gitoxin). Dtsch Gesundheitswes 18:1325–1333

    Google Scholar 

  • Reuning RH, Sams RA, Notari RE (1973) Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effects, kinetics and apparent volume of distribution of digoxin. J Clin Pharmacol 13:127–135

    Google Scholar 

  • Rietbrock N, Alken RG, Ebert W (1979) Vergleichende Untersuchung der absoluten Bioverfügbarkeit von vier oralen Digoxin-Präparaten. Arzneimittelforsch (Drug Res) 29:1742–1745

    Google Scholar 

  • Schlesinger J (1973) Fit to experimental data with exponential functions using the fast Fourier transform. Nucl Instrum Methods 106:503–508

    Google Scholar 

  • Storstein L (1976) Studies on digitalis. V. The influence of impaired renal function, hemodialysis, and drug interaction on serum protein binding of digitoxin and digoxin. Clin Pharmacol Ther 20:6–14

    Google Scholar 

  • Vöhringer HF, Rietbrock N, Spurny P, Kuhlmann J, Hampl H, Baethke R (1976) Disposition of digoxin in renal failure. Clin Pharmacol Ther 19:387–395

    Google Scholar 

  • Wagner JG, Popat KD, Das SK, Sakmar E, Movahhed H (1981) Evidence of nonlinearity in digoxin pharmacokinetics. J Pharmacokinet Biopharm 9:147–166

    Google Scholar 

  • Weiler EW, Lach HJ (1980) Direct radioimmunoassay for the determination of 16-acetyl-gitoxin in serum. Clin Chim Acta 104:337–343

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Haustein, K.O., Alken, R.G., Lach, H.J. et al. On the pharmacokinetics of pengitoxin and its cardioactive derivative 16-acetyl-gitoxin. Eur J Clin Pharmacol 25, 369–373 (1983). https://doi.org/10.1007/BF01037950

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01037950

Key words

Navigation